Dr. He Ruyi was appointed as a director on May 11, 2020, was transferred to an executive director on May 22, 2020, and was appointed as the company’s chief medical officer and clinical research director on May 11, 2020. He is mainly responsible for the management of the company’s clinical needs, medical support, clinical pharmacology, registration compliance, drug safety, clinical research and statistics.

Dr. He Ruyi has worked in the FDA of US, and NMPA, China for almost 20 years, including over 17 years in the FDA. He has held multiple strategic leadership positions and participated in the formulation of FDA guidelines in multiple therapeutic areas. While serving as the chief scientist of the Center for Drug Evaluation (CDE) of NMPA, China, he promoted a number of drug administration reforms. Dr. He Ruyi has published more than 20 research papers and abstracts in the fields of drug regulatory science and internal medicine. He received his bachelor’s and master’s degrees in medicine from China Medical University and his doctorate in internal medicine from Howard University in the US. He is a certified practicing physician in the US.